Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amit M Oza

Showing results (51-60 of 250) with videos related to

Pageof 25
Sort By:
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 22, 2020
Adjuvant treatment in early stage cervical cancer-does more equal better?Ainhoa Madariaga, Lawrence Kasherman, Kathy Han, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 11, 2020
Efficacy and safety updates of poly ADP-ribose polymerase (PARP) inhibitor maintenance in ovarian cancer from ASCO 2020Ainhoa Madariaga, Luisa Bonilla, Michelle McMullen, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 12, 2020
Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse eventsAinhoa Madariaga, Valerie Bowering, Soha Ahrari, et al.
Expert Opinion on Pharmacotherapy|February 27, 2016
Current and emerging treatment options in the management of advanced ovarian cancerVictor Rodriguez-Freixinos, Helen J Mackay, Katherine Karakasis, et al.
The Indian Journal of Medical Research|March 17, 2022
Updates on systemic therapy for cervical cancerPaul Gopu, Febin Antony, Sunu Cyriac, et al.
Cancer Treatment Reviews|March 3, 2012
Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancerIvan Diaz-Padilla, Ignacio Duran, Blaise A Clarke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2006
Impact and perceptions of mandatory tumor biopsies for correlative studies in clinical trials of novel anticancer agentsMark Agulnik, Amit M Oza, Gregory R Pond, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 2, 2016
Paradigm Shift in the Management Strategy for Epithelial Ovarian CancerKeiichi Fujiwara, Jessica N McAlpine, Stephanie Lheureux, et al.
Cancer|October 23, 2014
Intermediate clinical endpoints: a bridge between progression-free survival and overall survival in ovarian cancer trialsUrsula A Matulonis, Amit M Oza, Tony W Ho, et al.
European Journal of Cancer (Oxford, England : 1990)|December 3, 2014
Non-target progression--the fine line between objectivity and subjectivityStephanie Lheureux, Michelle K Wilson, Martin O'Malley, et al.
Pageof 25

Showing results (51-60 of 250) with videos related to

Sort By:
Pageof 25
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 22, 2020
Adjuvant treatment in early stage cervical cancer-does more equal better?Ainhoa Madariaga, Lawrence Kasherman, Kathy Han, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 11, 2020
Efficacy and safety updates of poly ADP-ribose polymerase (PARP) inhibitor maintenance in ovarian cancer from ASCO 2020Ainhoa Madariaga, Luisa Bonilla, Michelle McMullen, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 12, 2020
Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse eventsAinhoa Madariaga, Valerie Bowering, Soha Ahrari, et al.
Expert Opinion on Pharmacotherapy|February 27, 2016
Current and emerging treatment options in the management of advanced ovarian cancerVictor Rodriguez-Freixinos, Helen J Mackay, Katherine Karakasis, et al.
The Indian Journal of Medical Research|March 17, 2022
Updates on systemic therapy for cervical cancerPaul Gopu, Febin Antony, Sunu Cyriac, et al.
Cancer Treatment Reviews|March 3, 2012
Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancerIvan Diaz-Padilla, Ignacio Duran, Blaise A Clarke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2006
Impact and perceptions of mandatory tumor biopsies for correlative studies in clinical trials of novel anticancer agentsMark Agulnik, Amit M Oza, Gregory R Pond, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 2, 2016
Paradigm Shift in the Management Strategy for Epithelial Ovarian CancerKeiichi Fujiwara, Jessica N McAlpine, Stephanie Lheureux, et al.
Cancer|October 23, 2014
Intermediate clinical endpoints: a bridge between progression-free survival and overall survival in ovarian cancer trialsUrsula A Matulonis, Amit M Oza, Tony W Ho, et al.
European Journal of Cancer (Oxford, England : 1990)|December 3, 2014
Non-target progression--the fine line between objectivity and subjectivityStephanie Lheureux, Michelle K Wilson, Martin O'Malley, et al.
Pageof 25